Tag: Mercks
ESMO: Merck’s Keytruda-chemo combo shows survival ‘trend,’ but can’t top chemo...
Merck’s Keynote-361 study in newly diagnosed metastatic bladder cancer asked a key question: Could adding Keytruda to chemo improve on chemo, the standard of...
ESC: Merck’s Steglatro shows limited promise with heart failure hospitalization data
Late to the party against its SGLT2 diabetes rivals, Merck & Co.'s Steglatro has also tracked way behind in the class' growing presence in...
Merck’s Keytruda flops bladder cancer trial, giving Roche’s Tecentriq an open...
Merck & Co.’s Keytruda has several clinical wins under its belt that have led to a long list of FDA approvals. But it can’t...